Treatment usually consists of one-hour sessions, five days a week, for seven weeks.
Although manufacturers of this device had periodically presented information to HCFA, limited clinical and scientifically valid information precluded HCFA staff from issuing any positive coverage determination. The group receiving active therapy had a longer history of angina, higher percentage of myocardial infarction, and more residual 3-vessel disease. This change became effective July 1, 1999. Furthermore, coverage was limited to those enhanced external counterpulsation systems that have sufficiently demonstrated their medical effectiveness in treating patients with severe angina in well-designed clinical trials. Currently, both devices on the market represent a substantial improvement in technology from the original device.